RheumaGen
RheumaGen develops a class of cell and gene therapy treatments aimed at autoimmune diseases.
$15M Series A ·
Source: fundraisingfox.com
Latest round on record: Series A, December 2025, amount undisclosed.
All 2 rounds ↓Signals
Website registeredAug 12, 2020 (6 years old)
Funding rounds
- Series A · amount undisclosedSource: fundraisingfox.com
- Series A · $15MSource: fundraisingfox.com
- Website created
Founders and team
RF
Richard Freed CEO & Co-Foundersource: rheumagen.com- BFBrian Freed Chief Science Officer & Co-Foundersource: rheumagen.com
BH
Brian Hart COO & Co-FounderLinkedIn · source: rheumagen.com
Investors
Companies like RheumaGen
OOblenio Bio$62M Series B+ · Jun 2026
LLimula$6.8M Seed · Jun 2024
RRemedium$10M Series A · Aug 2026
RResolution TherapeuticsSeries B+ · Oct 2024
FForge Biologics$90M Series B+ · Sep 2022
AAbcuro$66M Series B+ · Aug 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/rheumagen (get a free API key).